Summal'y IP-10 is a member of the chemokine family of cytokines and is induced in a variety of cells in response to interferon 3' and lipopolysaccharide. The self-aggregation common to many chemokines, including IP-10, has hindered the identification of a specific Ipol0 receptor. Using an IPol0 alkaline phosphatase fusion protein that fortuitously blocks this self-aggregation, we have identified an IP-10 binding site on a variety of cells including endothelial, epithelial, and hematopoietic cells. This binding site has a Ka of 25 riM, is inhibited by recombinant murine or human IP-10, and is dependent on the presence of cell surface heparan sulfate proteoglycans (HSPG). This conclusion is based on the findings that IP-10 binding to cells is: (a) inhibited by heparin and heparan sulfate; (b) sensitive to a 1 M NaCI wash; (c) eliminated by treatment with heparinase and trypsin; and (d) absent on mutant CHO cells that do not express cell surface HSPG. Platelet factor 4 (PF4), but not IL-8, monocyte chemoattractant protein-I, RANTES, monocyte inflammatory protein (MIP)-lot, or MIP-I~/, can compete effectively with IP-10 for binding to the cell surface. Furthermore, IP-10 shares with PF4 the ability to inhibit endothelial cell proliferation (IC50 = 150 nM). These studies demonstrate specificity in the interaction of chemokines and HSPG, and they define IP-10 and PF4 as a distinct subset of chemokines sharing an HSPGbinding site and angiostatic properties.
Summal'y IP-10 is a member of the chemokine family of cytokines and is induced in a variety of cells in response to interferon 3' and lipopolysaccharide. The self-aggregation common to many chemokines, including IP-10, has hindered the identification of a specific Ipol0 receptor. Using an IPol0 alkaline phosphatase fusion protein that fortuitously blocks this self-aggregation, we have identified an IP-10 binding site on a variety of cells including endothelial, epithelial, and hematopoietic cells. This binding site has a Ka of 25 riM, is inhibited by recombinant murine or human IP-10, and is dependent on the presence of cell surface heparan sulfate proteoglycans (HSPG). This conclusion is based on the findings that IP-10 binding to cells is: (a) inhibited by heparin and heparan sulfate; (b) sensitive to a 1 M NaCI wash; (c) eliminated by treatment with heparinase and trypsin; and (d) absent on mutant CHO cells that do not express cell surface HSPG. Platelet factor 4 (PF4), but not IL-8, monocyte chemoattractant protein-I, RANTES, monocyte inflammatory protein (MIP)-lot, or MIP-I~/, can compete effectively with IP-10 for binding to the cell surface. Furthermore, IP-10 shares with PF4 the ability to inhibit endothelial cell proliferation (IC50 = 150 nM). These studies demonstrate specificity in the interaction of chemokines and HSPG, and they define IP-10 and PF4 as a distinct subset of chemokines sharing an HSPGbinding site and angiostatic properties. I P-10 was identified as an abundant RNA induced by IFN-3' and lipopolysaccharide (2, 3) and encodes a 10-kD secreted protein. It is a member of the -C-X-C-(or or) chemokine family of secreted 8-10-kD proteins and is 31% identical to platelet factor 4 (PF4) 1 and 26% identical to Ib8, two other members of the -C-X-C-chemokine family. IP-10 expression is induced in a variety of tissues in inflammatory conditions, such as psoriasis (4) , fixed drug eruptions (5), cutaneous delayed-type hypersensitivity reactions (6) , experimental glomerulonephritis (7) , and in experimental allergic encephalomyelitis (8) . IP-10 also has a potent in vivo antitumor effect that is T cell dependent (9) . IP-10 may be a chemoattractant for T cells and monocytes, and it may induce T cells to adhere to activated endothelial cells (10) , although these latter in vitro findings remain controversial (11) .
Chemokine receptors are known to be promiscuous, binding more than one chemokine, and various leukocytes are known 1 Abbreviations used in this paper: AP, alkaline phosphatase; bFGF, basic fibroblast growth factor; DHFR, dihydrofolate reductase; FBS, fetal bovine serum; h, human; HS, heparan sulfate; HSPG, HS proteoglycan; HUVEC, human umbilical cord vein endothelial cell; m, murine; MCP, monocyte chemoattractant protein; MIP, monocyte inflammatory protein; PF4, platelet factor 4; SEAP, secreted AP.
to have more than one chemokine receptor, making interpretation of binding data difficult. The recent molecular cloning of several chemokine receptors, including monocyte inflammatory protein (MIP)-lot/RANTES, monocyte chemoattractant protein (MCP)-I, and the erythrocyte chemokine receptors, as well as the demonstration of binding and signaling in heterologous cells, has been important in clarifying receptorligand interactions (12) . All the chemokine receptors cloned to date are members of the G protein-coupled seven transmembrane spanner family, and, with the exception of the promiscuous erythrocyte chemokine receptor (which is the Duffy blood group antigen), they induce transient rises in intracellular calcium upon activation. To date, however, a signaling receptor has not been identified for several chemokines, including IP-10 and the first chemokine to be identified, PF4. PF4 has been shown to bind to cell surface heparan sulfate proteoglycans (HSPG) (13, 14) and may, in fact, exert its biological effects of tumor inhibition and angiostasis by displacing growth factors such as basic fibroblast growth factor (bFGF) (15) and TGF-/~ (16) , which use cell surface HSPG as part of their receptor complexes.
To identify IP-10's cellular targets and to help clarify its physiological function and mechanism of signal transduction, we have set out to identify and characterize its specific cell in 30% L cell-conditioned medium (source of macrophage colonystimulating factor) and 20% FBS for 2 wk to obtain macrophages or 50% WEHI-conditioned medium (source of ID3) for 4 wk to obtain mast cells (21) .
Pro~'n Ex~ession and Purification. Recombinant murine IP-10 (2) beginning with the putative mature NH2-terminal Ile (nucleotide 129) and terminating with the COOH-terminal Pro (nucleotide 359) and human riP-10 (1) beginning with the mature NH2-terminal Val (nucleotide 132) and terminating with the COOH-terminal Pro (nucleotide 363) were engineered by PCR using the murine IP-10 (9) and human IP-10 (1) cDNAs as templates, respectively, into the Barn H1 site of the Qiaexpress vectors pQE12 and pQE8 (QIAGEN Inc., Chatsworth, CA) and then transformed into the Escherichia coli strain M15. Expression of IP-10 in pQE12 results in a fusion protein containing a (His)6 carboxy-terminal tag and expression of IP-10 in pQE8 results in a fusion protein containing an amino-terminal six histidine tag. In addition, both vectors also result in the addition of Met-Arg-Gly-Ser at the amino terminus of the His-tagged proteins, riP-10 was purified by sedimentation of inclusion bodies through sucrose, solubilization of the inclusion bodies in 4 M guanidine HC1, af~nity chromatography on nickel agarose (QIAGEN Inc.), and reverse phase HPLC (Waters Chromatography, Milford, MA). HPLC was performed on a C18 Vydac (Hespirio, CA) column (2.2 cm I.D.) at a flow rate of 9.5 ml/min, monitoring absorbance at 214 and 277 nm. The column was eluted with a linear gradient of increasing acetonitrile concentration. The specific conditions were: 5% B for 5 min, 5-50% B over 30 min, 50-90% B over 15 min, and then 95% B for 15 min with B being 80% acetonitrile/0.054% TFA acid and the remaining percentage being A, which was 0.06% TFA in water. For the studies reported in this paper, after HPLC purification and lyophilization, IP-10 was dissolved in PBS; however, it was subsequently found that IP-10 was more soluble and aggregated less when it was dissolved in water. The concentration of purified protein was determined with a Bradford assay (Bio-Rad Laboratories, Melville, NY) with BSA and bovine y-globulin as standards.
Two eukaryotic expression systems were used to express human IP-10: a murine Moloney virus long terminal repeat-based vector (9) transfected into J558L plasmacytoma cells and a dihydrofolate reductase (DHFR) resistance plasmid, pJOD-S (22), transfected into the double DHFR deletion mutant CHO line DG44 (23) . The complete human IP-10 coding sequence, the 5' Pstl-Clal fragment (nucleotides 1-384) of the human IP-10 cDNA, was blunt-end ligated into the EcoRI site ofa MoLTR-SV40 I/pA-expression vector that had been treated with the Klenow fragment of DNA polymerase. Transfection ofJ558L plasmacytoma cells was performed by electroporation (24) . 20 #g of linearized MoLTR-IP10 expression vector plasmid DNA and 1/~g of linearized neomycin resistance plasmid pSV7Neo were used to transfect 5 x 10 ~ cells. After 48 h in RPMI medium, cells were centrifuged and resuspended in selective media containing 0.8 mg/ml of G418 (as calculated for 100% antibiotic activity; Geneticin; GIBCO BRL) and plated in serial dilutions into 96 well plates to clone by limiting dilution. G418-resistant cells from single wells were expanded and a second round of cloning by limiting dilution in selective media was performed to ensure clonality. One clone, 4B6, expressing '~20 ng/ml IP-10, as determined by a solid-phase ELISA (9), was chosen as the source of secreted IP-10. To try to obtain higher levels of IP-10 secretion, a second eukaryotic expression system using a one-step methotrexate selection was used. For this purpose, the complete coding sequence of human IP-10 was engineered into the SalI site of the mammalian expression vector pJOD-S by blunt-end ligation. 200/~g of the expression plasmid pJOD-IPl0 linearized with lP-10 Shares a Cellular Binding Site with PF4 and Is Angiostatic bat II and 200 #g of sonicated herring sperm DNA were electroporated into the DHFR-deficient CHO clone DG44 as described (22) . A one-step amplification with 0.5 #M methotrexate (Sigma) was performed in 10% dialyzed FBS and MEM-cr lacking ribonudeotides and deoxyribonucleotides (GIBCO BRL). Individual clones were picked after 14 d of selection by ring isolation and expanded. 25 clones were initially assayed for the level of IP-10 expression by Northern blot and immunoblot using rabbit antiIPl0 antiserum. Clone 12D3G4 expressed ~10 ng/ml of IP-10 (as determined subsequently by ELISA) and was chosen as the source of secreted IP-10. Conditioned medium from transfected cells grown in serum free medium (Nutridoma from Boehringer Mannheim for J558L; CHO-S-SFM from GIBCO BILL for CHO cells) was collected and passed over a heparin Sepharose column (Pharmacia Fine Chemicals, Piscataway, NJ). After step elutions with a NaC1 gradient, an aliquot of each fraction was analyzed by SDS-PAGE and Western blotting using an affinity-purified rabbit anti-IP-10 antibody (25) . The fraction containing IP-10 immunoreactive material was then purified by reverse-phase HPLC using the acetonitrile gradient previously described. HPLC fractions were then analyzed by SDS-PAGE on a 12.5% SDS-polyacrylamide gel using a Tris/Tricine buffer system (26) that has good resolution in the low molecular weight region, followed by either Coomassie staining or Western blotting using rabbit anti-human IP-10 antisera (see below). IP-10 purified from J558L and CHO had the same appearance on SDS-PAGE.
Antibody Preparation. For immunizations, both human and mufine IP-10 were purified from E. coli as described above, except that the eluate from the nickel-agarose chromatography column was separated on a denaturing SDS-polyacrylamide gel. The region of the gel containing IP-10 was cut out and emulsified with complete Freund's adjuvant for the primary immunization and with incomplete Freund's adjuvant for subsequent immunizations. Three 8-wk-old female New Zealand white rabbits were injected subcutaneously with ~200 mg per rabbit of the carboxy-terminal tagged protein (IP-10-(His)6). The rabbits were boosted twice, at 1-mo intervals, with 100 mg of the amino-terminal tagged protein ((His)6-IP-10) per rabbit to ensure the generation of antibodies recognizing the native NHz and COOH termini of IP-10. 10 d after the second boost, the three rabbits were bled, and the serum was isolated and a portion was pooled for affinity purification. Affinity purification of antiserums was performed as described (25) using the His-tagged riP-10 coupled to CNBr-activated Sepharose beads (Pharmacia).
Radiolabeling rlP-lO. IP-10 purified from E. coli was labeled with the 12sI Bolton and Hunter reagent (Amersham) according to the manufacturers instructions and unincorporated 12SI-Bolton and Hunter reagent was removed on a NAP-5 column (Pharmacia). The Bolton and Hunter reagent was chosen to radiolabel Ipol0 because IP-10 contains no tyrosines amenable to chemical modification with mI. Radiolabeled IP-10 (specific activity = 154 ng/#Ci) was also supplied by Dr. Garth Brown (NEN/DuPont) who radiolabeled PeproTech IP-10 by the Bolton and Hunter method and then purified it by reverse phase HPLC.
Production of lP-IO-AP Fusion Protein. Human and murine IP-10 was expressed as a soluble fusion protein with the secreted form of placental alkaline phosphatase (AP) by engineering the human and mouse cDNAs for IP-10 into the APtag vector (27) . This was accomplished by PCR using the 5' primer CGCAAGCTTCGG-GAGACATTCCTCAATTGC and the 3' primer CGCGGATC-CAGGAGATCTTTTAGACATTTC for human IP-10, as well as the 5' primer ACAGATCTAAGCGCTTCATCCACCGCTGA and the 3' primer GCGAGATCTAGGAGCCCTTTTAGACCTTTT for murine IP-10 and the human and mouse IP-10 cDNA clones as templates, respectively. After digestion of the human PCK product with HindlII and BamHI and the mouse PCK product with BgllI, they were ligated into the HindlII/BgllI and BgllI site of the APtag vector, respectively. This resulted in fusion proteins that contained the authentic signal sequences and entire mature proteins fused in flame with secreted AP (SEAP) via the four-amino acid linker GlySer-Ser-Gly for human IP-10 and Arg-Ser-Ser-Gly for murine IP-10.
The IP-10-APtag phsmids linearized with Sail were co-transfected with the selectable marker pSV7neo into NIH-3T3 cells by the calcium phosphate method. After selection with 0.4 rag/m1 G418 (GIBCO BRL) in 96-well plates (6.4 mm per well), "~100 individual clones were screened for secreted alkaline phosphatase activity. This assay was performed by heating 50 #1 of the supernatant at 65~ for 10 min to inactivate background cellular phosphatase activity and then measuring the A40s on a V~, kinetic microplate reader (Molecular Devices, Menlo Park, CA) after incubating with 1 M diethanolamine, pH 9.8, 0.5 mM MgC12, 10 mM L-homoarginine (a phosphatase inhibitor), and 12 mM p-nitrophenyl phosphate (Sigma), all prepared as a 2 x stock solution (SEAP buffer). The highest expressing NIH-3T3 clones, 18.G5 for murine and 17.G2 for human IP-10-AP produced 1,000 mOD/ml per min and 800 mOD/ml per rain, respectively, were used for the experiments described in this paper. A control NIH-3T3 clone expressing unfused SEAP was produced by transfecting with plasmid pBC12/CMV/ SEAP. Other control fusion proteins such as, human and murine IL-4-AP and kit-AP were kindly provided by Drs. B. Morrison (Dana Farber Cancer Institute, Boston, MA) and J. Flannagan (Harvard Medical School, Boston, MA), respectively.
To determine the specific activity of the proteins, the concentration of IP-10-AP in the supernatant was estimated by quantitative immunoprecipitation (see below) followed by SDS-PAGE with Coomassie blue staining and comparing the intensity of Coomassie staining compared to BSA standard dilution. To determine the efficiency of immunoprecipitation, the amounts of AP activity in the initial sample and the remaining AP activity next two sequential immunoprecipitations were determined and used as a correction factor to calculate for <100% efficiency of immunoprecipitation. The resulting estimate for the specific activity of murine IP-10-AP was 30 mOD/min per ng, which is similar to the specific activity determined for Ib4-AP (100 mOD/min per ng; reference 38).
Immunoprecipitation and Immunoblotting. 1 ml of conditioned media from the NIH-3T3 clone 18.G5 secreting mIP-10-AP was collected, centrifuged at 1,000 g, and protease inhibitors (Boehringer Mannheim Biochemicals) were added to the supernatant at the following concentrations: leupeptin (0.3 ng/ml), aprotinin (10 ng/ml), PMSF (20 ng/ml), and pepstatin (0.8 ng/ml). The supernatant was then centrifuged at 10,000 g for 30 min at 4~ and then precleared for 4 h at 4~ with 50 #1 of a 1:1 slurry of protein A-Sepharose (PAS) (Pharmacia). The PAS was then centrifuged at 10,000 g in eppendorf tubes, and 50 #1 of a 1:1 slurry of a mAb to placental AP (catalogue No. A-018-02; Medix Biotech, Foster City, CA) coupled to CNBr-activated Sepharose (Pharmacia) was added to the supernatant for 2 h at 4~ The beads were recovered by centrifugation at 10,000 g for 10 rain and a second immunoprecipitation was performed by adding another 50 #1 of a 1:1 slurry of mAbSepharose beads and incubating for another 2 h at 4~ The immunoprecipitates were then washed 3 x with 1 ml of KIPA buffer (0.15 M NaC1, 1% NP-40, 0.1% SDS, 0.5% deoxycholate, 0.05 M Tris, pH 8.0) and then boiled for 3 min in 50 #1 of sample buffer containing 0.3 M 2-ME, 4% SDS. 20 #1 was then analyzed on a Laemmli 10% SDS-polyacrylamide gel and the intensity of Coomassie staining was compared to a dilution series of BSA.
For immunoblotting, gds were transferred to Immobilon-P mem-branes (Millipore Corp., Bedford, MA) with a semidry transblotter (Owl Scientific, Woburn, MA) blocked with 3% nonfat dry milk/3% goat serum (Sigma)/PBS and incubated with a 1:10,000 dilution of affinity-purified rabbit anti-IP-10 antiserum for 2 h at room temperature. The membranes were then washed 2 x 10 min each with PBS/.1% Tween 20, lx 10 min with RIPA buffer, and then 2x 10 min each with PBS/.1% Tween 20, and then incubated with a 1:20,000 dilution of peroxidase-conjugated goat anti-rabbit IgG (catalogue No. 111-035-003; Jackson ImmunoResearch Laboratories, West Grove, PA) for I h at room temperature in 3% nonfat milk and 3% goat serum in PBS. The membrane was then washed as described above and developed using an ECL chemiluminescence kit (Amersham).
Binding Assays. For nonadherent cells, 107 cells were washed lx with ice-cold binding buffer (HBSS/10 mM Hepes/0.1% BSA) and resuspended in the indicated concentration of IP-10-AP and competitors in a total of 100 #1 ice-cold binding buffer. Binding was carried out for 2 h on ice with occasional mixing. Cells were washed 5 x with ice-cold binding buffer by repeated centrifugation at 4~ Cell-bound AP activity was determined by lysing cells in 100/~1 of 10 mM "Iris, pH 8.0/1% Triton X-100, heating at 65~ for 10 min to inactivate cellular AP, and then centrifuging at 14,000 g for 10 min. 50/zl of the soluble lysate was then mixed with 50/~1 2 x SEAP buffer in a 96-well plate at room temperature, and the colormetric product was assayed in a kinetic plate reader at A40s. For adherent cells with higher numbers of binding sites, binding was determined in six-well cluster plates. Cells were washed 2 x with ice-cold binding buffer and incubated with the indicated concentration of IP-10-AP and competitor in a total of 500/~1 of ice-cold binding buffer for 2 h in the cold room on a rocker platform. Cells were washed 6 x with binding buffer, lysed with 100/~1 of 10 mM Tris, pH 8.0/1% Triton X-100, scraped into an Eppendorf tube, and then assayed as described above. Nonspecific binding was determined in one of two ways. For the calculation of the equilibrium constant, nonspecific binding was determined by adding 10 mM riP-10 at each concentration of IP-10-AP and performing the binding experiments in parallel exactly as described above. Heparinase and Trypsin Treatment. For adherent calls, 106 cells were washed lx with serum-free DMEM and then incubated in 500/~1 serum-free DMEM at 37~ and 5% CO2 for 1 h with either 2.5 U/m1 heparinase I or 0.2 U/m1 heparinase III (heparitinase) (29) . For nonadherent ceils, 107 cells were washed lx with serumfree RPMI and resuspended in 100 #1 RPMI plus the concentrations of Heparinase I and III indicated above. After enzyme treatment, adherent cells were washed 4 x with 5 ml binding buffer and nonadherent cells were washed 2 x with 10 ml binding buffer, then assayed for IP-10-AP binding as described above. Calcium Flux. THP-1, A20, and EL4 cells were resuspended at 2 x 106 cells per ml in RPMI 1640 containing 2% FBS and 5/~g/ml Fura 2-am (Molecular Probes Inc., Eugene, OR) (diluted from a 1 mg/ml stock in dimethyl sulfoxide). THP-1 cells were incubated for 1 h, and A20 and EL4 cells were incubated for 30 min at 37~ and were then washed three times in 145 mM NaC1, 4 mM KC1, 1 mM NaH2PO4, 0.8 mM MgCI2, 1.8 mM CaC12, 10 mM glucose, and 25 mM Hepes (pH 7.4). Cells were resuspended at 106 cells per ml in this buffer, and 2-ml samples were loaded into a fluorimeter (LS-5B; Perkin-Elmer Cetus Corp., Norwalk, CT) for measurements ofintracellular calcium. Excitation and emission wavelengths were 399 and 510 nm, respectively. Maximum calcium-Fura 2 fluorescence was measured after treating loaded cells with 1% Triton X-100 and minimum calcium-Fura 2 fluorescence was measured after the addition of 100 mM Tris, pH 8.0 and 100 mM EGTA.
Results

Purification of rlP-lO Expressed in E. coli. Human and mu-
rine IP-10 were generated as recombinant proteins tagged at either the NH2 or COOH terminus with (His)6. Both NH2 terminally and COOH terminally His-tagged IP-10 were generated to minimize the possibility that the (His)6 tag could interfere with receptor binding and biological activity or mask a potentially important epitope when raising antibodies to riP-10. IP-10 was purified by sedimentation of inclusion bodies (which contained the insoluble recombinant protein) through sucrose, solubilization of the inclusion bodies in 4 M guanidine HC1, affinity chromatography on nickel agarose, and then reverse-phase HPLC eluting with an acetonitrile gradient (Fig. 1 A) . Although there appears to be a shoulder on the IP-10 peak, SDS-PAGE analysis of fractions across this peak revealed a homogenous protein. II>-10 was then radiolabeled with 12SI-Bolton and Hunter reagent and subjected to reducing SDS-PAGE (Fig. 1 B) . Under these purification conditions, IP-10 appears to aggregate into multimers. At the exposure shown in Fig. 1 B monomers and dimers are evident; but at longer exposures and on heavily loaded Coomassie-stained gels, higher order multimers are seen. These multimers are reactive with affinity-purified rabbit anti-IP-10 antiserum and are unaffected by reduction and irreversible alkylation of sulfhydryls (data not shown). This aggregation is not the result of the (His)6 tag, since a non- ( Fig. 1 B) .
Purification of rlP-lO
Secreted from J558L Plasmacytoma and CHO Cells. Since IP-10 purified from E. coli aggregated, it was of interest to determine if IP-10 purified from eukaryotic cells and not subjected to denaturation and renaturation would also aggregate. The complete IP-10 cDNA was therefore engineered into the two expression vectors, MoLTR/SV-40 I/pA and pJOD-S, and then stably transfected into J558L and CHO cells, respectively. IP-10 was secreted from both stably transfected lines in similar amounts as judged by a solidphase ELISA and had similar electrophoretic mobility profiles. IP-10 was purified from conditioned medium by heparin Sepharose affinity chromatography followed by reverse-phase HPI.C (Fig. 2) . This purification demonstrates that IP-10 binds to heparin Sepharose at physiological NaC1 concentrations and is eluted beteween 0.5 M and L0 M NaC1 (Fig. 2 A) . The 1-M eluate from the heparin Sepharose column was subjected to reverse-phase HPLC analysis (Fig. 2 B) . Fractions eluted with a gradient of increasing acetonitrile were analyzed by SDS-PAGE and immunoblotted with an affinitypurified anti-IP-10 antiserum (Fig 2 C) . The fraction containing immunoreactive IP-10 is indicated on the chromatogram in Fig. 2 B by an arrow. IP-10 secreted and purified from eukaryotic cells also aggregates under these purification and dectrophoresis conditions (Fig. 2, A and C) . The aggregation of the E. coli synthesized material is therefore not unique to the bacterial product and reflects a property of the molecule.
Furthermore, the E. coli-and J558Loproduced IP-10 have the same reverse phase HPLC elution profile (compare position of curved arrow on chromatogram in Fig. 1 A with position of curved arrow on chromatogram in Fig. 2 B) , suggesting they have similar properties.
IP-IO-AP Binding to Cells is Specific, Saturable, and Competed by PF4.
Since radiolabeled riP-10 produced in E. coli aggregated in solution and on cell surfaces (see below), it was impossible to identify a specific saturable IP-10 binding site. To overcome this problem, IP-10 was expressed as an AP fusion gene that, when introduced into mammalian cells, resulted in the secretion of a nonaggregating monomeric fusion protein that bound to cells via its NH2-terminal IP-10 epitope and enzymatically assayed via its COOH-terminal AP tail (Fig. 3) . Both murine (m) and human (h)Ipol0 were engineered into the APtag vector and initially used for binding studies. However, since no species specificity was apparent and the murine fusion protein had less nonspecific binding, all data presented in this report used the murine IP-10-AP AP fusion protein (IP-10-AP). The specific activity of the IP-10-AP was estimated by determining the amount of AP activity in I ml of conditioned medium and then estimating the amount of IP-10-AP protein by quantitative immunoprecipitation using an mAb specific for AP.
Using IP-10-AP, we have been able to demonstrate that IP-10 binds specifically to a variety of cells and binds with a Ka of 25 nM on A20 B cells (Fig. 4 A) . IP-10-AP binding was 100% inhibited by 10 #M recombinant murine or human IP-10 on A20 B cells and EL4 T cells; however, when other chemokines were tested for their ability to compete for Ipo 10-AP binding to A20 B cells and EL4 T cells, only hPF4 could inhibit 100% of mlP-10-AP binding. At ",~100-fold molar excess, hlL-8, hMIP-lol, hMIP-1B, hRANTES had virtually no effect, but hMCP-1 did partially compete (data not shown). Since hMCP-1 partially competed in one experiment, we performed a dose-inhibition experiment comparing mlP-10, hPF4, and hMCP-1 (Fig. 4 B) . In this experiment, while hPF4, mlP-10, and heparin (see below) could compete for IP-10-AP binding to cells in a dose-dependent manner, hMCP-1 had no effect on mlP-10-AP, binding even at 100 #g/ml ("~10 #M or *600-fold molar excess). The discrepancy between the two experiments could relate to a change in the source of hMCP-1 (initially from Genentech and then from PeproTech). O f note, the inhibition curve using E. coli produced IP-10 was shifted to the right probably because the effective molarity of the IP-10 solution was lower than expected because of the aggregation of riP-10.
IP-IO-AP Inhibits the Aggregation of lP-lO on Cells.
To test the hypothesis that the AP tail of the IP-10-AP fusion protein was inhibiting the aggregation of IP-10 on the cell sur- .r '10 .c_ Fig. 6 A demonstrates that the binding of mlP-10-AP to THP-1 cells can be inhibited by excess human or mouse IP-10, but not by hMIP-lot or hMIP-1/3. HL60 cells do not bind mlP-10-AP and were included as a negative control. As can be seen in Fig. 6 B, THpol cells loaded with Fura-2 were able to demonstrate a transient calcium flux upon stimulation with hMCP-1, hRANTES, and hMIP-lot, but were unable to flux calcium upon addition of hlpol0. Furthermore, hiP-10 was unable to desensitize THP-1 cells to subsequent hMCP-1 or h R A N T E S stimulation. In contrast, hMIP-lot desensitized THP-1 cells to subsequent hRANTES or hMCP-1 stimulation. In addition, heparin and heparan sulfate (100 ng/ml), molecules that augment IL-8 signal transduction (31), did not enable I1)-10 to signal (data not shown).
Glycosaminoglycan Inhibition of lP-lO Binding. Heparin and
heparan sulfate were able to completely block IP-10-AP binding to cells in a concentration-dependent manner (Fig. 7) . Chondroitin sulfate B (dermatan sulfate) was also able to inhibit IP-10-AP binding to A20 B cells, but at higher concentrations than heparin or heparan sulfate. In contrast, chondroitin sulfate A had no effect on IP-10-AP binding, even at I mg/ml, whereas heparin and HS completely inhibited IP-10-AP binding at 10 #g/ml. In fact, heparin's inhibition curve was almost superimposable on PF4's inhibition curve (Fig. 4 B) .
Cellular Distribution of lP-10 Binding Sites. Table 1 
IP-IO Binding to Cells is Dependent on Surface HSPG.
Since heparin and heparan sulfate inhibited IP-10-AP binding to cells, and IP-10-AP binding sites were found in higher numbers on adherent cell lines, we tested whether this binding site is salt and heparinase sensitive. Fig. 8 A demonstrates that the IP-10-AP binding site on fibroblasts is also competed for by heparin and excess IP-10, and that it is sensitive to heparinase treatment and an 1-M NaC1 wash. Heparinase I treatment of BALB/c-3T3 cells enzymatically removed "~75% of the IP-10-AP binding sites while having no effect on kit-AP binding to the kit ligand. Heparinase III also removed "~84% of the IP-10-AP binding sites on NIH-3T3 cells (data not shown). This is also true for the binding site on A20 B cells, where Heparinase I and III removed 100 and 75%, respectively (data not shown). In addition, after binding and washing in HBSS, a l-rain wash in HBSS adjusted to 1 M NaC1 removed all of the IP-10-AP from BALB/c-3T3 and only 50% of kit-AP from these same cells. The IP-10 binding site is also sensitive to trypsin digestion on three cell lines tested, NIH-3T3, BALB/c-3T3, and SVEC, a mouse endothelial cell line (Fig. 8 B) . A further demonstration that IP-10 binding is dependent on cell surface heparan sulfate comes from studies using two CHO mutants that lack HSPG because of mutations in enzymes that are necessary for glycosaminoglycan biosynthesis. As can be seen in Fig.  9 , IP-10-AP binds to wild-type parental CHO line K1, but does not bind to either of the mutant lines, 677 and 803. Furthermore, soluble heparan sulfate does not restore binding to the mutants, but in fact, inhibits the binding of IP-10-AP to the wild-type CHO cells in a concentration-dependent fashion.
IP-IO Inhibits HUVEC Proliferation. Since PF4 was able to compete with IP-10 for binding to several cell lines tested, including A20 B cells and NIH 3T3 cells, and since PF4 was known to inhibit bFGF-induced proliferation of endothelial cells, the effect of IPol0 on the growth of HUVECs was tested (Fig. 10 A) . Like PF4, which has an IC50 of 100-200 nM, IP-10 half maximally inhibits HUVEC proliferation at 150 nM (1.5/~g/ml). However, it required at least fivefold more IP-10 to reach 100% inhibition compared to PF4, which again may reflect a propensity of IP-10 to aggregate at high concentrations, decreasing its effective molarity. The inhibition by submaximal concentrations of PF4 and IP-10 are additive (data not shown). As is the case for PF4, increasing concentrations of exogenous heparin reverses the inhibitory effects Nondetectable indicates there was no significant binding over background binding. Background binding was determined using either cross-species IL4-AP or secreted AP binding to cells. Number of sites per cell was determined by using the specific activity estimated for IP-10-AP (30 mOD/min per ng). of IP-10 upon proliferation, just as it does to the inhibitory effects of PF4 (Fig. 10 B) . 
Discussion
One of the major problems in studying the properties of IP-10 was that, like other chemokines (32, 33) , IP-10 selfaggregates at physiological pH and tonicity. This aggregation interfered with our ability to identify a specifc and saturable Ipol0 cellular binding site. To overcome this problem, we generated an IP-10-AP fusion protein that retained its ability to bind to cells, but that did not aggregate in physiological buffers. Using this fusion protein, we demonstrated that IP-10 binds to a cell surface HSPG receptor with a Kd of 25 nM. The conclusion that this receptor is a HSPG rests on the observations that cellular IPol0 binding is inhibited by heparin and HS, eliminated by treatment with heparinase and trypsin, and absent on mutant CHO cells that do not express cell surface HSPG.
The binding of IP-10 to its HSPG receptor is a specific interaction. Only PF4 and certain glycosaminoglycans compete for IP-10 binding to cells. Heparin and heparan sulfate are equipotent in competing for IP-10 binding sites, while chondroitin sulfate B is >--100 fold less potent and chondroitin sulfate A is unable to compete for these sites. Further, PF4 is as potent as heparin in competing with IP-10 binding to cells, while IL-8, R.ANTES, MIP-lo~, MIP-I~, and MCP-1 have virtually no inhibitory effect on IP-10. Although IL-8 binds heparin and is almost as homologous to IP-10 as PF4 (26 vs 31%), it does not effectively compete for IP-10's cellular HSPG sites. Interestingly, human and murine IP-10 competed with murine IP-10-AP and with human IP-10-AP for cellular binding (data not shown), suggesting that there is no binding specificity between these species. It is also striking that Ipol0 is less potent on a weight basis than either PF4 or heparin in competing with IP-10-AP binding. This observation is consistent with the formation of Ipol0 aggregates, decreasing its effective molar concentration. Aggregation may also explain the fourfold lower Ka found for IP-10 binding to soluble heparin as compared with IP-IO-AP binding to cells. Since the monomeric fusion protein IP-10 binds to cells, aggregation of IP-10 is not required for binding to its HSPG receptor. Our approach of using a fusion protein to inhibit self-aggregation might be generally applicable to other chemokines.
We also demonstrated that like PF4, IP-10 inhibits bFGFinduced proliferation of endothelial cells. Moreover, heparin antagonizes this inhibition, suggesting that the antiproliferative effect of IP-10 is mediated through this same HSPG receptor. The specific HSPG site that PF4 and IP-10 share may be a physiologically relevant site at which these molecules modulate the action of other cytokines that use HSPG as part of their receptor complex. For example, PF4 can inhibit both bFGF (15) and TGF-~ (16) binding to cells. Indeed, this may be the mechanism whereby PF4 and IP-10 exert their antiproliferative effects and may explain the growth regulating properties that the chemokines have on many diverse cell types (34) (35) (36) (37) .
Our results do not exclude the possibility that there is another receptor for IP-10. Nonetheless, we were unable to detect an IP-10 binding site on human peripheral lymphocytes, even though it has been reported that IP-10 is a chemotactic for peripheral blood T cells (10) . Furthermore, we have been unable to detect a calcium flux in cells that specifically bind IP-10. It nonetheless remains quite possible that by fusing IP-10 to AP, we have destroyed the ability of IP-10 to interact with its signaling receptor while preserving its ability to interact with a specific HSPG-binding site. Although this is possible, other, albeit nonchemokine alkaline phosphatase fusion proteins (e.g., human and mouse IL-4 [38] , kit [27] , and fibroblast growth factor receptor (FGFR) [39] ) retain their ability to interact with their specific cell-surface receptor or ligands.
One other role for heparin and cell surface HSPG is in enhancing signaling of cytokines to their signaling receptor chains. For example, FGF signaling through its tyrosine kinase receptor, FGFK1, requires either soluble or cell surface-bound HSPG (40) . The HSPG receptor betaglycan is also involved in TGF-/3 signaling. Betaglycan presents TGF-/3 directly to the serine/threonine kinase subunit of the signaling receptor, forming a high affinity ternary complex (41) . It has been demonstrated that heparin and heparan sulfate enhance neutrophil responses to IL-8 (31) and augment the ability of MIP-1/3 (42) to induce T cell adhesion. The mechanism of this enhancement has not been examined and, indeed, it is not known whether cell surface HSPG or soluble heparin is actually required for chemokines to bind to and signal through their seven transmembrane spanner receptors. This question could be experimentally approached by comparing the ligand binding and signaling properties of wild-type and HSPG-deficient CHO cells that have been transfected with cloned chemokine receptors.
Chemokines are known to bind to heparin, and it has been proposed from studies that found immunoreactive MIP-1B in the distribution of endothelial cells that they bind cell surface HSPG (42) . HSPG on cell surfaces may capture chemokines from the fluid phase, thereby immobilizing and establishing a gradient of chemokine that can then be presented to rolling leukocytes and perhaps serve as a substrate for chemotaxis or hapotaxis (43) . The specificity of the chemokine-HSPG interaction may play a role in regulating leukocyte homing and the recruitment of leukocytes to sites of inflammation. This could be accomplished through the differential expression of specific HSPG on endothelial cells in different tissues, or through the induction of specific HSPG by specific inflammatory stimuli. The expression of HSPGs with affinity for only a subset of chemokines in a given microenvironment would then allow only those chemokines captured in that microenvironment to be presented to rolling leukocytes. Thus, those chemokines with affinity for the regionally expressed or induced HSPG would be able to more effectively deliver a signal to circulating leukocytes. This hypothesis has not been explored for the chemokines, but the concept of HSPG-ligand specificity dictating a biological response has been established for the FGF family (44) .
Constitutive expression of IP-10 is seen in the thymus and in the spleen, and high levels of expression are seen in various inflammatory conditions. It is therefore useful to consider the possibility that IP-10 plays a role in regulating immune and inflammatory responses by modulating the action of other cytokines that use HSPG as part of their receptor complex. Both IP-10 and PF4 have been demonstrated to inhibit the growth of tumors (9, 45) , possibly through immunologic, inflammatory, and/or angiostatic mechanisms. PF4 is in fact now in clinical trials as an antitumor agent. In preliminary experiments, we have shown that injection of IP-10 into a tumor transplant site has an antitumor effect (Luster, A. D., and P. Leder, unpublished observation). In considering the pharmacological delivery of IP-10 or PF4 to tumors, one should bear in mind HSPG receptors may be expressed on the tumor cells themselves, as well as on the endothelial and inflammatory cells that may be a part of the effector mechanism in the antitumor response.
